Royal North Shore Hospital, St Leonards, NSW, Australia.
North Shore Private Hospital, St Leonards, NSW, Australia.
J Vasc Access. 2024 May;25(3):981-987. doi: 10.1177/11297298231165642. Epub 2023 Apr 8.
Vascular access via a single arterial catheter for targeted chemotherapy delivery has difficulties with concentration, dilution, drug retention, plasma binding, and lack of control of the tumour microcirculation. An implantable arterial access system to accommodate multi-catheter access was developed address these problems. The system was also adapted for isolated arterial-to-arterial extracorporeal suprasystolic perfusion for end stage peripheral vascular disease. The arterial-to-arterial logistics were compared with standard venovenous and arteriovenous fistulae access employed in haemodialysis.
Targeted chemotherapy delivery was addressed in a pilot study of vascular liver isolation. Ten patients with secondary colorectal cancer, were treated with multiple infusions employing up to five individually steered catheters. The arterial-to-arterial extracorporeal access system was also used to treat end stage peripheral vascular disease in 20 patients where amputation was the only option. The trial was named Hypertensive Extracorporeal Limb Perfusion (HELP).
Multiple day only infusions produced a partial response or stable disease in six out of the ten patients in an 'end stage' setting. The mean survival was 11.2 months. Of the twenty patients facing amputation 40% had avoided amputation at follow-up 22 months and 20% had delay of 4 months.
The access system allows repeatable steerable multi-catheter arterial access for chemotherapy delivery to address difficulties of concentration, dilution, plasma binding and microvascular control. The access system supports multiple repeatable suprasystolic extracorporeal arterial to arterial access. It is cardiac independent generating flows of greater than 1 L/min with zero flow in between treatments. The device logistics compares favourably with arteriovenous and venovenous access systems.
通过单个动脉导管进行靶向化疗给药的血管通路存在浓度、稀释、药物保留、血浆结合以及缺乏对肿瘤微循环控制等问题。为了解决这些问题,开发了一种可容纳多导管接入的植入式动脉接入系统。该系统还适用于孤立的动脉到动脉体外超射灌注治疗终末期外周血管疾病。将动脉到动脉物流与血液透析中使用的标准动静脉和动静脉瘘接入进行了比较。
在血管肝脏隔离的初步研究中解决了靶向化疗给药的问题。10 名患有继发性结直肠癌的患者接受了多达 5 根单独导向导管的多次输注治疗。动脉到动脉的体外通路系统还用于治疗 20 名面临截肢的终末期外周血管疾病患者。该试验命名为高血压体外肢体灌注(HELP)。
在“终末期”环境中,10 名患者中有 6 名患者仅进行多天输注就产生了部分缓解或稳定疾病。平均生存时间为 11.2 个月。在面临截肢的 20 名患者中,40%的患者在随访 22 个月时避免了截肢,20%的患者截肢时间推迟了 4 个月。
该接入系统允许可重复的可控多导管动脉接入,用于化疗给药,以解决浓度、稀释、血浆结合和微血管控制的困难。该接入系统支持多次可重复的超射体外动脉到动脉接入。它是心脏独立的,产生的流量大于 1L/min,在治疗之间为零流量。该设备物流与动静脉和静脉动脉接入系统相比具有优势。